Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus chemotherapy in untreated extensive-stage small cell lung cancer
NCT03711305Phase 3Unknown
- Sponsor
- Hengrui
- Start
- Dec 2018
- Primary completion
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Adebrelimab + Chemo with Placebo + Chemo (2 arms). Primary endpoint: Overall Survival. Status: unknown.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03711305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03711305.